ANZCTR - Registration

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers

Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04740905

Registration number

NCT04740905

Ethics application status

Date submitted

3/02/2021

Date registered

5/02/2021

Date last updated

6/08/2024

Titles & IDs

Public title

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion

Scientific title

A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion

Secondary ID [1]

2020-000440-63

Secondary ID [2]

GR41984

Universal Trial Number (UTN)

Trial acronym

BALATON

Linked study record

Health condition

Health condition(s) or problem(s) studied:

Macular Edema

Branch Retinal Vein Occlusion

Condition category

Condition code

Eye

Diseases / disorders of the eye

Cardiovascular

Diseases of the vasculature and circulation including the lymphatic system

Intervention/exposure

Study type

Interventional

Description of intervention(s) / exposure

Treatment: Drugs - Faricimab
Treatment: Drugs - Aflibercept
Treatment: Surgery - Sham Procedure

Experimental: Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2) - In Part 1 (Day 1 through Week 24), participants randomly assigned to Arm A will receive faricimab 6 milligrams (mg) by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections). In Part 2 (from Week 24 to Week 72), participants will receive faricimab 6 mg by IVT injection according to a personalized treatment interval (PTI) dosing regimen. To preserve masking for Part 2, a sham procedure will be administered during study visits at which no faricimab treatment is administered (according to the PTI dosing regimen).

Active comparator: Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2) - In Part 1 (Day 1 through Week 24), participants randomly assigned to Arm B will receive aflibercept 2 milligrams (mg) by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections). In Part 2 (from Week 24 to Week 72), participants will receive faricimab 6 mg by IVT injection according to a personalized treatment interval (PTI) dosing regimen. To preserve masking for Part 2, a sham procedure will be administered during study visits at which no faricimab treatment is administered (according to the PTI dosing regimen).

Treatment: Drugs: Faricimab
Faricimab will be administered by intravitreal (IVT) injection as specified in each treatment arm.

Treatment: Drugs: Aflibercept
Aflibercept 2 mg will be administered by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections).

Treatment: Surgery: Sham Procedure
The sham is a procedure that mimics an intravitreal (IVT) injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.

Intervention code [1]

Treatment: Drugs

Intervention code [2]

Treatment: Surgery

Comparator / control treatment

Control group

Outcomes

Primary outcome [1]

Part 1: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye at Week 24

Timepoint [1]

From Baseline through Week 24

Secondary outcome [1]

Part 1: Change From Baseline in BCVA in the Study Eye at Specified Timepoints Through Week 24

Timepoint [1]

Baseline, Weeks 4, 8, 12, 16, 20, and 24

Secondary outcome [2]

Part 1: Percentage of Participants Gaining =15 Letters in BCVA From Baseline in the Study Eye at Week 24

Timepoint [2]

Baseline and Week 24

Secondary outcome [3]

Part 1: Percentage of Participants Gaining =15 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24

Timepoint [3]

Baseline, Weeks 4, 8, 12, 16, 20, and 24

Secondary outcome [4]

Part 1: Percentage of Participants Gaining =10 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24

Timepoint [4]

Baseline, Weeks 4, 8, 12, 16, 20, and 24

Secondary outcome [5]

Part 1: Percentage of Participants Gaining =5 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24

Timepoint [5]

Baseline, Weeks 4, 8, 12, 16, 20, and 24

Secondary outcome [6]

Part 1: Percentage of Participants Gaining >0 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24

Timepoint [6]

Baseline, Weeks 4, 8, 12, 16, 20, and 24

Secondary outcome [7]

Part 1: Percentage of Participants Avoiding a Loss of =15 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24

Timepoint [7]

Baseline, Weeks 4, 8, 12, 16, 20, and 24

Secondary outcome [8]

Part 1: Percentage of Participants Avoiding a Loss of =10 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24

Timepoint [8]

Baseline, Weeks 4, 8, 12, 16, 20, and 24

Secondary outcome [9]

Part 1: Percentage of Participants Avoiding a Loss of =5 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24

Timepoint [9]

Baseline, Weeks 4, 8, 12, 16, 20, and 24

Secondary outcome [10]

Part 1: Percentage of Participants Achieving =84 Letters in BCVA (20/20 Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 24

Timepoint [10]

Baseline, Weeks 4, 8, 12, 16, 20, and 24

Secondary outcome [11]

Part 1: Percentage of Participants Achieving =69 Letters in BCVA (20/40 or Better Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 24

Timepoint [11]

Baseline, Weeks 4, 8, 12, 16, 20, and 24

Secondary outcome [12]

Part 1: Percentage of Participants With =38 Letters in BCVA (20/200 or Worse Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 24

Timepoint [12]

Baseline, Weeks 4, 8, 12, 16, 20, and 24

Secondary outcome [13]

Part 1: Change From Baseline in Central Subfield Thickness in the Study Eye at Specified Timepoints Through Week 24

Timepoint [13]

Baseline, Weeks 4, 8, 12, 16, 20, and 24

Secondary outcome [14]

Part 1: Percentage of Participants With Absence of Macular Edema in the Study Eye at Specified Timepoints Through Week 24

Timepoint [14]

Baseline, Weeks 4, 8, 12, 16, 20, and 24

Secondary outcome [15]

Part 1: Percentage of Participants With Absence of Intraretinal Fluid in the Study Eye at Specified Timepoints Through Week 24

Timepoint [15]

Baseline, Weeks 4, 8, 12, 16, 20, and 24

Secondary outcome [16]

Part 1: Percentage of Participants With Absence of Subretinal Fluid in the Study Eye at Specified Timepoints Through Week 24

Timepoint [16]

Baseline, Weeks 4, 8, 12, 16, 20, and 24

Secondary outcome [17]

Part 1: Percentage of Participants With Absence of Intraretinal Fluid and Subretinal Fluid in the Study Eye at Specified Timepoints Through Week 24

Timepoint [17]

Baseline, Weeks 4, 8, 12, 16, 20, and 24

Secondary outcome [18]

Part 1: Change From Baseline in National Eye Institute 25-Item Visual Functioning Questionnaire (NEI VFQ-25) Composite Score at Week 24

Timepoint [18]

Baseline and Week 24

Secondary outcome [19]

Parts 1 and 2: Change From Baseline in BCVA in the Study Eye at Specified Timepoints Through Week 72

Timepoint [19]

Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

Secondary outcome [20]

Parts 1 and 2: Percentage of Participants Gaining =15 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 72

Timepoint [20]

Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

Secondary outcome [21]

Parts 1 and 2: Percentage of Participants Gaining =10 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 72

Timepoint [21]

Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

Secondary outcome [22]

Parts 1 and 2: Percentage of Participants Gaining =5 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 72

Timepoint [22]

Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

Secondary outcome [23]

Parts 1 and 2: Percentage of Participants Gaining >0 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 72

Timepoint [23]

Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

Secondary outcome [24]

Parts 1 and 2: Percentage of Participants Avoiding a Loss of =15 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 72

Timepoint [24]

Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

Secondary outcome [25]

Parts 1 and 2: Percentage of Participants Avoiding a Loss of =10 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 72

Timepoint [25]

Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

Secondary outcome [26]

Parts 1 and 2: Percentage of Participants Avoiding a Loss of =5 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 72

Timepoint [26]

Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

Secondary outcome [27]

Parts 1 and 2: Percentage of Participants Achieving =84 Letters in BCVA (20/20 Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 72

Timepoint [27]

Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

Secondary outcome [28]

Parts 1 and 2: Percentage of Participants Achieving =69 Letters in BCVA (20/40 or Better Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 72

Timepoint [28]

Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

Secondary outcome [29]

Parts 1 and 2: Percentage of Participants With =38 Letters in BCVA (20/200 or Worse Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 72

Timepoint [29]

Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

Secondary outcome [30]

Parts 1 and 2: Change From Baseline in NEI VFQ-25 Questionnaire Composite Score at Specified Timepoints Through Week 72

Timepoint [30]

Baseline and Weeks 24, 48, and 72

Secondary outcome [31]

Parts 1 and 2: Change From Baseline in Central Subfield Thickness in the Study Eye at Specified Timepoints Through Week 72

Timepoint [31]

Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

Secondary outcome [32]

Parts 1 and 2: Percentage of Participants With Absence of Macular Edema in the Study Eye at Specified Timepoints Through Week 72

Timepoint [32]

Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

Secondary outcome [33]

Parts 1 and 2: Percentage of Participants With Absence of Intraretinal Fluid in the Study Eye at Specified Timepoints Through Week 72

Timepoint [33]

Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

Secondary outcome [34]

Parts 1 and 2: Percentage of Participants With Absence of Subretinal Fluid in the Study Eye at Specified Timepoints Through Week 72

Timepoint [34]

Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

Secondary outcome [35]

Parts 1 and 2: Percentage of Participants With Absence of Intraretinal Fluid and Subretinal Fluid in the Study Eye at Specified Timepoints Through Week 72

Timepoint [35]

Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

Secondary outcome [36]

Part 2: Change From Week 24 in BCVA in the Study Eye at Specified Timepoints Through Week 72

Timepoint [36]

Weeks 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

Secondary outcome [37]

Part 2: Percentage of Participants Avoiding a Loss of =15 Letters in BCVA From Week 24 in the Study Eye at Specified Timepoints Through Week 72

Timepoint [37]

Weeks 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

Secondary outcome [38]

Part 2: Percentage of Participants Avoiding a Loss of =10 Letters in BCVA From Week 24 in the Study Eye at Specified Timepoints Through Week 72

Timepoint [38]

Weeks 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

Secondary outcome [39]

Part 2: Percentage of Participants Avoiding a Loss of =5 Letters in BCVA From Week 24 in the Study Eye at Specified Timepoints Through Week 72

Timepoint [39]

Weeks 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

Secondary outcome [40]

Part 2: Percentage of Participants Avoiding a Loss of >0 Letters in BCVA From Week 24 in the Study Eye at Specified Timepoints Through Week 72

Timepoint [40]

Weeks 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

Secondary outcome [41]

Part 2: Percentage of Participants on Different Treatment Intervals at Week 68

Timepoint [41]

Week 68

Secondary outcome [42]

Part 2: Number of Study Drug Injections Received in the Study Eye From Week 24 Through Week 72

Timepoint [42]

From Week 24 to Week 72

Secondary outcome [43]

Incidence and Severity of Ocular Adverse Events in the Study Eye, With Severity Determined According to Adverse Event Severity Grading Scale

Timepoint [43]

Part 1: From first dose up to Week 24; Part 2: from Week 24 through Week 72

Secondary outcome [44]

Incidence of Ocular Adverse Events in the Fellow Eye

Timepoint [44]

Part 1: From first dose up to Week 24; Part 2: from Week 24 through Week 72

Secondary outcome [45]

Incidence of Non-Ocular Adverse Events

Timepoint [45]

Part 1: From first dose up to Week 24; Part 2: from Week 24 through Week 72

Secondary outcome [46]

Plasma Concentration of Faricimab Over Time

Timepoint [46]

Predose at Day 1 (Baseline), Weeks 4, 24, 28, 52, and 72

Secondary outcome [47]

Number of Participants With Anti-Drug Antibodies (ADAs) to Faricimab at Baseline and Post-Baseline During the Study

Timepoint [47]

Predose at Day 1 (Baseline), Weeks 4, 24, 28, 52, and 72

Eligibility

Key inclusion criteria

* Foveal center-involved macular edema due to branch retinal vein occlusion (BRVO), diagnosed no longer than 4 months prior to the screening visit
* Best-corrected visual acuity (BCVA) of 73 to 19 letters, inclusive (20/40 to 20/400 approximate Snellen equivalent) on Day 1
* Sufficiently clear ocular media and adequate pupillary dilatation to allow acquisition of good quality retinal images to confirm diagnosis
* For women of childbearing potential: agreement to remain abstinent or use contraception, and agreement to refrain from donating eggs during the treatment period and for 3 months after the final dose of study treatment

Minimum age

18 Years

Maximum age

No limit

Sex

Both males and females

Can healthy volunteers participate?

Key exclusion criteria

* Any major illness or major surgical procedure within 1 month before screening
* Uncontrolled blood pressure
* Stroke (cerebral vascular accident) or myocardial infarction within 6 months prior to Day 1
* Pregnant or breastfeeding, or intending to become pregnant during the study

Ocular Exclusion Criteria for Study Eye:

* History of previous episodes of macular edema due to RVO or persistent macular edema due to RVO diagnosed more than 4 months before screening
* Any current ocular condition which, in the opinion of the investigator, is currently causing or could be expected to contribute to irreversible vision loss due to a cause other than macular edema due to RVO in the study eye (e.g., ischemic maculopathy, Irvine-Gass syndrome, foveal atrophy, foveal fibrosis, pigment abnormalities, dense subfoveal hard exudates, or other non-retinal conditions)
* Macular laser (focal/grid) in the study eye at any time prior to Day 1
* Panretinal photocoagulation in the study eye within 3 months prior to Day 1 or anticipated within 3 months of study start on Day 1
* Any prior or current treatment for macular edema; macular neovascularization, including diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD); and vitreomacular-interface abnormalities, including, but not restricted to, IVT treatment with anti-VEGF, steroids, tissue plasminogen activator, ocriplasmin, C3F8, air or periocular injection
* Any prior intervention with verteporfin photodynamic therapy, diode laser, transpupillary thermotherapy, or vitreo-retinal surgery including sheatotomy
* Any prior steroid implant use including dexamethasone intravitreal implant (Ozurdex) and fluocinolone acetonide intravitreal implant (Iluvien)

Ocular Exclusion Criteria for Both Eyes:

* Prior IVT administration of faricimab in either eye
* History of idiopathic or autoimmune-associated uveitis in either eye
* Active periocular, ocular or intraocular inflammation or infection (including suspected) in either eye on Day 1

Study design

Purpose of the study

Treatment

Allocation to intervention

Randomised controlled trial

Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)

Methods used to generate the sequence in which subjects will be randomised (sequence generation)

Masking / blinding

Blinded (masking used)

Who is / are masked / blinded?

The people receiving the treatment/s

The people assessing the outcomes
The people analysing the results/data

Intervention assignment

Parallel

Other design features

Phase

Phase 3

Type of endpoint/s

Statistical methods / analysis

Recruitment

Recruitment status

Completed

Data analysis

Reason for early stopping/withdrawal

Other reasons

Date of first participant enrolment

Anticipated

Actual

2/03/2021

Date of last participant enrolment

Anticipated

Actual

Date of last data collection

Anticipated

Actual

12/06/2023

Sample size

Target

Accrual to date

Final

553

Recruitment in Australia

Recruitment state(s)

NSW,VIC,WA

Recruitment hospital [1]

Strathfield Retina Clinic - Strathfield

Recruitment hospital [2]

Save Sight Institute - Sydney

Recruitment hospital [3]

Sydney Retina Clinic and Day Surgery - Sydney

Recruitment hospital [4]

Centre For Eye Research Australia - East Melbourne

Recruitment hospital [5]

Retina Specialists Victoria - Rowville

Recruitment hospital [6]

The Lions Eye Institute - Nedlands

Recruitment postcode(s) [1]

2135 - Strathfield

Recruitment postcode(s) [2]

2000 - Sydney

Recruitment postcode(s) [3]

3002 - East Melbourne

Recruitment postcode(s) [4]

3178 - Rowville

Recruitment postcode(s) [5]

6009 - Nedlands

Recruitment outside Australia

Country [1]

United States of America

State/province [1]

Arizona

Country [2]

United States of America

State/province [2]

California

Country [3]

United States of America

State/province [3]

Colorado

Country [4]

United States of America

State/province [4]

Connecticut

Country [5]

United States of America

State/province [5]

Florida

Country [6]

United States of America

State/province [6]

Georgia

Country [7]

United States of America

State/province [7]

Hawaii

Country [8]

United States of America

State/province [8]

Illinois

Country [9]

United States of America

State/province [9]

Maryland

Country [10]

United States of America

State/province [10]

Massachusetts

Country [11]

United States of America

State/province [11]

Michigan

Country [12]

United States of America

State/province [12]

Minnesota

Country [13]

United States of America

State/province [13]

Missouri

Country [14]

United States of America

State/province [14]

Nevada

Country [15]

United States of America

State/province [15]

New Jersey

Country [16]

United States of America

State/province [16]

New York

Country [17]

United States of America

State/province [17]

North Carolina

Country [18]

United States of America

State/province [18]

Ohio

Country [19]

United States of America

State/province [19]

South Dakota

Country [20]

United States of America

State/province [20]

Tennessee

Country [21]

United States of America

State/province [21]

Texas

Country [22]

United States of America

State/province [22]

Utah

Country [23]

Argentina

State/province [23]

Caba

Country [24]

Argentina

State/province [24]

Capital Federal

Country [25]

Argentina

State/province [25]

Ciudad Autonoma Buenos Aires

Country [26]

Argentina

State/province [26]

Mendoza

Country [27]

Argentina

State/province [27]

Rosario

Country [28]

Argentina

State/province [28]

San Nicolás

Country [29]

Austria

State/province [29]

Graz

Country [30]

Brazil

State/province [30]

Country [31]

Brazil

State/province [31]

Country [32]

Brazil

State/province [32]

Country [33]

China

State/province [33]

Beijing

Country [34]

China

State/province [34]

Changchun

Country [35]

China

State/province [35]

Chengdu

Country [36]

China

State/province [36]

Guangzhou City

Country [37]

China

State/province [37]

Harbin

Country [38]

China

State/province [38]

Nanjing City

Country [39]

China

State/province [39]

Shanghai

Country [40]

China

State/province [40]

Shenyang City

Country [41]

China

State/province [41]

Tianjin City

Country [42]

China

State/province [42]

Wenzhou City

Country [43]

China

State/province [43]

Wuhan

Country [44]

China

State/province [44]

Zhengzhou

Country [45]

Czechia

State/province [45]

Ostrava

Country [46]

Czechia

State/province [46]

Prague

Country [47]

Czechia

State/province [47]

Sokolov

Country [48]

France

State/province [48]

Creteil

Country [49]

France

State/province [49]

Paris

Country [50]

Germany

State/province [50]

Freiburg

Country [51]

Germany

State/province [51]

Göttingen

Country [52]

Germany

State/province [52]

Ludwigshafen

Country [53]

Hong Kong

State/province [53]

Hong Kong

Country [54]

Hong Kong

State/province [54]

Mongkok

Country [55]

Hungary

State/province [55]

Budapest

Country [56]

Hungary

State/province [56]

Debrecen

Country [57]

Hungary

State/province [57]

Pécs

Country [58]

Hungary

State/province [58]

Szeged

Country [59]

Israel

State/province [59]

Haifa

Country [60]

Israel

State/province [60]

Jerusalem

Country [61]

Israel

State/province [61]

Petach Tikva

Country [62]

Israel

State/province [62]

Rehovot

Country [63]

Israel

State/province [63]

Tel Aviv

Country [64]

Italy

State/province [64]

Lazio

Country [65]

Italy

State/province [65]

Lombardia

Country [66]

Italy

State/province [66]

Toscana

Country [67]

Japan

State/province [67]

Aichi

Country [68]

Japan

State/province [68]

Chiba

Country [69]

Japan

State/province [69]

Fukuoka

Country [70]

Japan

State/province [70]

Fukushima

Country [71]

Japan

State/province [71]

Hokkaido

Country [72]

Japan

State/province [72]

Hyogo

Country [73]

Japan

State/province [73]

Ibaraki

Country [74]

Japan

State/province [74]

Kyoto

Country [75]

Japan

State/province [75]

Tokushima

Country [76]

Japan

State/province [76]

Tokyo

Country [77]

Korea, Republic of

State/province [77]

Busan

Country [78]

Korea, Republic of

State/province [78]

Daegu

Country [79]

Korea, Republic of

State/province [79]

Seongnam-si

Country [80]

Korea, Republic of

State/province [80]

Seoul

Country [81]

Poland

State/province [81]

Bydgoszcz

Country [82]

Poland

State/province [82]

Bytom

Country [83]

Poland

State/province [83]

Gda?sk

Country [84]

Poland

State/province [84]

Gliwice

Country [85]

Poland

State/province [85]

Katowice

Country [86]

Poland

State/province [86]

Kraków

Country [87]

Poland

State/province [87]

Piaseczno

Country [88]

Poland

State/province [88]

Rybnik

Country [89]

Poland

State/province [89]

Tarnowskie Góry

Country [90]

Poland

State/province [90]

Warszawa

Country [91]

Portugal

State/province [91]

Coimbra

Country [92]

Portugal

State/province [92]

Porto

Country [93]

Russian Federation

State/province [93]

Baskortostan

Country [94]

Russian Federation

State/province [94]

Tatarstan

Country [95]

Russian Federation

State/province [95]

Irkutsk

Country [96]

Singapore

State/province [96]

Singapore

Country [97]

Spain

State/province [97]

Navarra

Country [98]

Spain

State/province [98]

Valencia

Country [99]

Spain

State/province [99]

Barcelona

Country [100]

Spain

State/province [100]

Madrid

Country [101]

Spain

State/province [101]

Valladolid

Country [102]

Taiwan

State/province [102]

Changhua

Country [103]

Taiwan

State/province [103]

Taipei

Country [104]

Taiwan

State/province [104]

Taoyuan

Country [105]

Taiwan

State/province [105]

Zhongzheng Dist.

Country [106]

United Kingdom

State/province [106]

Belfast

Country [107]

United Kingdom

State/province [107]

Bristol

Country [108]

United Kingdom

State/province [108]

Cardiff

Country [109]

United Kingdom

State/province [109]

Gloucestershire

Country [110]

United Kingdom

State/province [110]

Leeds

Country [111]

United Kingdom

State/province [111]

London

Funding & Sponsors

Primary sponsor type

Commercial sector/industry

Name

Hoffmann-La Roche

Address

Country

Other collaborator category [1]

Commercial sector/industry

Name [1]

Chugai Pharmaceutical

Address [1]

Country [1]

Ethics approval

Ethics application status

Summary

Brief summary

This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled, parallel-group study evaluating the efficacy, safety, and pharmacokinetics of faricimab administered by intravitreal (IVT) injection at 4-week intervals until Week 24, followed by a double-masked period of study without active control to evaluate faricimab administered according to a personalized treatment interval (PTI) dosing regimen in participants with macular edema due to branch retinal vein occlusion (BRVO).

Trial website

https://clinicaltrials.gov/study/NCT04740905

Trial related presentations / publications

Public notes

Contacts

Principal investigator

Name

Clinical Trials

Address

Hoffmann-La Roche

Country

Phone

Fax

Contact person for public queries

Name

Address

Country

Phone

Fax

Contact person for scientific queries

Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT04740905

Trial Review

Did you know?

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04740905